mynth
03/2026MajorityLBO

Siparex takes majority stake in Winncare

FRANCE Life Sciences / Medical Devices REV €100–200M

Context

Siparex has reaffirmed its commitment to Winncare by leading a quaternary LBO to retain control of the medical device manufacturer. This transaction allows Siparex, which originally acquired the company in 2021 via its ETI 5 fund, to extend the maturity of its investment while slightly increasing its ownership stake alongside the management team led by President Laurent Faugères. The deal marks a significant restructuring of the minority capital: IDI, which had been an investor since 2014, and Capza have both exited their positions. They are replaced by Kartesia, which entered the capital through a combination of equity and mezzanine debt after a competitive process managed by the investment bank Amala. The strategic rationale for this "prolongation" is driven by Winncare,s strong performance, having doubled its revenue from €75M to €150M in the last five years through a successful buy-and-build strategy involving four acquisitions. The new capital structure is designed to provide the group with the financial flexibility to launch a new phase of consolidation in Europe and North America. The deal is supported by a new senior debt package provided by Crédit Agricole CIB, while historical minority partners BNP Paribas Développement and Crédit Agricole have maintained their stakes. This operation highlights the "essential" nature of Winncare,s products in a market characterized by high demand for elderly care solutions and professionalized home-care equipment.

The acquisition of Winncare is part of the growth strategy of Siparex, which already has several external growth operations under its belt, notably 123 Elec in 2026.

Winncare, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

Winncare is a leading European manufacturer of medical devices specifically designed for the care of individuals with loss of autonomy. The company,s product portfolio includes high-tech anti-bedsore mattresses, medicalized beds, and patient-handling solutions aimed at improving the quality of life for the elderly and those in rehabilitation. Operating with an industrial business model, Winncare supplies its essential medical equipment to nursing homes, hospitals, and home-care providers globally. Its value proposition is built on technical innovation and the reliability of its "first-necessity" products, which address the growing healthcare demands of an aging global population. The group,s strategy centers on being a consolidation platform in the specialized medical furniture market, leveraging a robust R&D pipeline to maintain regulatory compliance and clinical efficacy. By integrating digital solutions into its hardware, Winncare ensures better patient monitoring and caregiver efficiency. The company maintains a strong international presence, focusing on expanding its manufacturing and distribution footprint across Europe and North America through both organic innovation and strategic industrial acquisitions.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2025
€100–200M
€5–25M
[members only]
2024
€100–200M
€5–25M
[members only]

Other operations with Winncare

Other operations with Winncare
DateAcquirerTargetCountrySector
12/2021WINNCAREPHARMAOUEST INDUSTRIESFRANCEMedical Devices
02/2021SIPAREXWINNCAREFRANCEMedical Devices

Other operations with Siparex

Other operations with Siparex
DateAcquirerTargetCountrySector
10/2026SIPAREX / BPIFRANCE / CARVEST (CRÉDIT AGRICOLE RÉGIONS INVESTISSEMENT)SATYS ELECTRICFRANCECabling & Connectivity
09/2026SIPAREXKOALYSFRANCETIC (Testing, Inspection, Certification)
03/2026SIPAREXATK SPORTSITALYOutdoor
01/2026SIPAREX123 ELECFRANCESpecialized E-commerce
01/2026SIPAREX / SOCADIF / BNP PARIBAS DEVELOPPEMENTNOVAKAMPFRANCEAerospace, Naval & Defense
10/2025SIPAREX / BPIFRANCEBRIFER (LA FERROVIAIRE DE LA BRIE)FRANCERailways
04/2025SIPAREXNOOUSFRANCERecruitment / Headhunting
03/2025SIPAREXLABORATOIRE POLIDISFRANCEMedical Consumables
07/2023SIPAREXGROUPE PASSMANFRANCEIT Equipment
05/2023SIPAREXSODIKARTFRANCECycling & Micromobility

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
04/2026REVENIO GROUP CORPORATIONVISIONIX INTERNATIONALFRANCEDiagnostic Equipment
04/2026GILEAD SCIENCESARCELLXUNITED STATESR&D Biotech
03/2026RESONETICSRESOLUTION MEDICALUNITED STATESMedical Devices
03/2026ABBOTT LABORATORIESEXACT SCIENCESUNITED STATESDiagnostic Equipment
03/2026DEUTSCHE BETEILIGUNGS (DBAG)HIPP TECHNOLOGY GROUPGERMANYImplants & Prosthetics
03/2026LONE STAR FUNDSLONZA CHISWITZERLANDCDMO
02/2026CIMGDAREN TECHNOLOGYCHINAR&D Biotech
02/2026IMA GROUPPROSYSIRELANDMedical Devices
02/2026VIVO CAPITALDUTSCHERFRANCEMedical Consumables
02/2026NORD HOLDINGHALLMARQ VETERINARY IMAGINGUNITED KINGDOMDiagnostic Equipment

REFERENCES

Revenue range: REV €100–200M

EBITDA range: €5–25M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Winncare by Siparex are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: winncare

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Winncare, a French company specialised in Medical Devices, by Siparex in 2026, structured as a leveraged buyout (LBO). This followed an earlier holding cycle initiated in February 2021, when the company was acquired by Siparex.

What were Winncare’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Winncare generated annual revenue estimated in the €100–200M range and EBITDA in the €5–25M bracket (FY 2025). Detailed financial figures are available to members.

What sources support the information on this transaction?

The details of this transaction are sourced directly from the official corporate announcement published on the parties’ institutional website, ensuring primary-source verification of the closing and perimeter.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.